Skip to main content

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Integra Therapeutics Collaborate to Advance Gene Therapy

Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announced that it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. According to the announcement, the collaboration was created to pursue a novel method to enhance Integra Therapeutics’ ability to use gene editing for future cancer therapies. Integra Therapeutics selected Predictive Oncology due to the company’s protein expression experience and unique ability to optimize solubility and physical stability for expressed proteins. “This collaboration could set the stage for new discoveries in cell therapy,” said Integra’s CEO Avencia Sanchez-Mejias. “We are excited about the potential that Predictive Oncology offers in advancing our goals in advanced therapies.”

To view the full press release, visit https://ibn.fm/5uoMC

About Predictive Oncology Inc.

As a science-driven company on the leading-edge of oncology drug discovery, Predictive Oncology offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world’s largest privately held biobank of over 150K tumor samples. Predictive Oncology’s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.